Mizuho Securities Reaffirms Their Buy Rating on Evolus (EOLS)

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Evolus (EOLS – Research Report) yesterday and set a price target of $25.00. The company’s shares closed yesterday at $9.30.

Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Evolus, and Tectonic Therapeutic. According to TipRanks, Ear has an average return of -3.5% and a 35.85% success rate on recommended stocks.

Evolus has an analyst consensus of Strong Buy, with a price target consensus of $24.29, implying a 161.18% upside from current levels. In a report released on May 27, BTIG also reiterated a Buy rating on the stock with a $21.00 price target.

Based on Evolus’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $68.07 million and a GAAP net loss of $18.89 million. In comparison, last year the company earned a revenue of $59.33 million and had a GAAP net loss of $13.11 million

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EOLS in relation to earlier this year. Most recently, in March 2025, Karah Herdman Parschauer, a Director at EOLS sold 12,888.00 shares for a total of $167,415.12.